Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA funding increase on hold

Executive Summary

The agency and most of the federal government continue to operate at fiscal 2008 spending levels following the Senate's inability to approve an omnibus appropriations measure. The House on Feb. 25 adopted the $410 billion FY '09 appropriations package, which includes nine spending bills and a 19 percent increase in FDA money (1"The Pink Sheet" DAILY, Feb. 23, 2009). But Republicans opposed the bill's high price tag and have tied up the measure in the Senate. Additional Republican amendments are scheduled for March 9 and "we are hoping for a final vote" March 10, according to a spokesman for Senate Appropriations Chair Daniel Inouye, D-Hawaii. In the meantime, affected agencies are covered by a continuing resolution that expires March 11

You may also be interested in...



House Omnibus Approps Bill Would Increase FDA Spending By 19% In Fiscal 2009

FDA directed to use additional money to improve drug, device and food safety.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail

Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.

Topics

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel